• Arash Mosarrezaii, Danial Tahazadeh, Hussein Soleimantabar, and Pegah Panahi.
• Department of Neurology, School of Medicine, Neurophysiology Research Center, Cellular and Molecular Medicine Research Institute, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran.
• Pain Manag Nurs. 2024 Aug 13.

BackgroundMigraine is a prevalent episodic headache that affects approximately 14%-15% of the global population. Since valsartan is an antihypertensive drug, it is hypothesized that taking valsartan can prevent migraine attacks in patients with the condition. This study aimed to determine the efficacy of propranolol versus valsartan in preventing migraine attacks.Material And MethodsThis randomized controlled trial was conducted on 56 patients with migraine from a neurology clinic. Patients were divided into two equal groups of 28 individuals, after providing informed consent. The patients then received either propranolol or valsartan treatment. The intensity and frequency of migraines were compared before and after treatment in both study groups.ResultsThe patients' mean age was 32.78 years old (±6.9 SD), and 64% of the patients were female. After a 1-month treatment period, the results showed that valsartan patients experienced significantly fewer severe migraine attacks compared to propranolol patients.ConclusionAccording to the results of the present study, valsartan may be at least as effective as propranolol and perhaps more effective on some measures.Copyright © 2024. Published by Elsevier Inc.

4 keywords...

hide…